Pro-inflammatory cytokine network

The pro-inflammatory cytokine network is a complex, integrated system of signaling molecules that mediate and amplify inflammatory responses (Dinarello, 2000, "Proinflammatory Cytokines", Chest). It primarily consists of cytokines such as Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), which are released by activated immune cells like macrophages and dendritic cells (Zhang & An, 2007, "Cytokines, Inflammation, and Cancer", World Journal of Gastroenterology). These molecules bind to specific high-affinity receptors on target cells, triggering intracellular signaling cascades—most notably the NF-kappaB and JAK-STAT pathways—that lead to the expression of inflammatory genes and the recruitment of additional leukocytes (McInnes & Schett, 2011, "The Pathogenesis of Rheumatoid Arthritis", New England Journal of Medicine). While essential for host defense against pathogens, chronic or excessive activation of this network is central to the pathogenesis of various autoimmune and inflammatory diseases, including rheumatoid arthritis, Crohn's disease, and psoriasis (Feldmann & Maini, 2001, "TNF defined as a therapeutic target", Nature Medicine). Therapeutic strategies often involve the use of monoclonal antibodies or decoy receptors to neutralize specific cytokines or block their receptors, thereby dampening the systemic inflammatory response (Taylor et al., 2001, "Anti-tumor necrosis factor therapies", Current Opinion in Rheumatology).

Other names

Inflammatory cytokine cascadePro-inflammatory signaling networkCytokine networkCytokine storm pathway

Therapeutic agents modulate the network by binding to and neutralizing circulating cytokines, competitively inhibiting cytokine receptors, or inhibiting intracellular kinases (such as Janus kinases) that mediate cytokine signaling (O'Shea et al., 2013, "Janus kinases in immune cell signaling", New England Journal of Medicine).